China’s NDRC Issues Anti-Monopoly Law's Priciest Fine Ever On Two Chinese Firms Manipulating Raw Ingredient Sales
This article was originally published in PharmAsia News
Executive Summary
Is NDRC sending a message that the pharma industry is too important to be left to industry regulation alone?
You may also be interested in...
What Does China's Price Manipulation Ruling On Unilever Mean For Global Pharma? (Part 1 of 2)
SHANGHAI - The National Development and Reform Commission, China's state planning agency, charged consumer goods company Unilever a fine of RMB 2 million ($310,000) for price manipulation May 6. The NDRC action was taken in an effort to suppress consumer inflation, but a key takeaway, according to experts, is that multinational companies should be cautious about how they communicate pricing information to the market or they may find themselves in violation of China's Price Law, Anti-Monopoly Law or even foreign antitrust and anti-bribery rules
Key Role For China As Sanofi’s Emerging Markets Business Grows
Continuing with a double-digit growth rate, China remained a leading driver for Sanofi’s global business in the fourth quarter. Going digital and building local partnerships emerged as key themes for Sanofi China to explore more opportunities, although it may face testing problems for its vaccine business in the country.
Deal Watch: Avid Transitions Into CDMO By Offloading Cancer Program To Oncologie
Oncologie acquires PS-targeting candidate bavituximab, which may help other cancer therapies in attacking tumors. BridgeBio's newest spinout will develop former Novartis cancer candidate infigratinib.